Tranexamic Acid for Heavy Menstrual Bleeding: Guidelines and Precautions

Contraindications and Cautions

• The American Heart Association recommends avoiding tranexamic acid in women with spontaneous coronary artery dissection (SCAD) due to its association with myocardial infarction and thrombosis 1
• Tranexamic acid should be used with caution in patients with cardiovascular disease, such as SCAD, due to theoretical thrombotic concerns 1, 2, 3
• Reduced doses of tranexamic acid are mandatory in patients with renal impairment, as it is primarily renally excreted, with a higher risk of neurotoxicity and ocular toxicity 4
• The FDA contraindicates tranexamic acid in patients with a history of thrombosis or thromboembolism, as well as those with an intrinsic risk for thrombosis 5

Comparative Effectiveness

• The levonorgestrel-releasing intrauterine system reduces menstrual blood loss more than tranexamic acid, with a 71-95% reduction 5

Clinical Algorithm

• The American College of Cardiology and other guideline societies recommend screening for absolute contraindications, such as active thrombosis, DIC, and history of thromboembolism, before initiating tranexamic acid therapy 1
• Renal function should be assessed and the dose of tranexamic acid adjusted if impaired, to minimize the risk of neurotoxicity and ocular toxicity 4

Cautions for Using Tranexamic Acid (TXA) in Idiopathic Menorrhagia

Key Contraindications and Cautions

• Tranexamic acid should be used with caution in patients with idiopathic menorrhagia who are taking oral contraceptive pills due to increased thrombotic risk, and is contraindicated in patients with disseminated intravascular coagulation, active thromboembolic disease, or history of thrombosis 6
• TXA is contraindicated in disseminated intravascular coagulation (DIC) as it may worsen the condition 6
• TXA should be used with caution in patients with massive hematuria due to risk of ureteric obstruction 6
• Reduced doses of TXA are recommended in patients with renal dysfunction as renal clearance is the major mechanism of excretion, with a higher risk of neurotoxicity and ocular toxicity in renal impairment 7

Timing and Administration Considerations

• If surgery is planned, consider discontinuing TXA 5 days before procedures with high bleeding risk or surgery in confined spaces (brain, posterior chamber of eye, medullary canal) 6